NIH Discovers New Potent Opioid for Safer Pain Relief Without Side Effects

Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that may serve as a therapy for both pain management and opioid use disorder. Announced on April 1, 2026, the discovery centers on a drug compound that provides significant pain relief without the typical markers of addiction or dangerous side effects.

In a study published in the journal Nature, the research team observed the effects of the new drug in laboratory animals. The findings indicated that the compound delivers high pain-relieving effects without causing tolerance, respiratory depression, or other indicators of potential addiction in humans.

The discovery is particularly significant because respiratory depression is the primary cause of death following an opioid overdose. By decoupling potent analgesia from these life-threatening side effects, the NIH researchers aim to provide a safer alternative to current gold-standard pain medications.

The Engineering of Modified Nitazenes

The scientific team focused their investigation on nitazenes, an understudied class of synthetic opioid compounds. Nitazenes selectively engage mu-opioid receptors, which are the primary targets for opioid drugs within the peripheral nervous system and the brain.

Although these compounds were explored in the 1950s, they were shelved due to their excessive potency. Some modified nitazenes are reported to be 1,000 times stronger than morphine, making them too dangerous for clinical use at the time.

The NIH team revisited this class of compounds with the goal of harnessing their selectivity for the mu-opioid receptor while engineering a safer pharmacological profile. Michael Michaelides, Ph.D., a NIDA investigator and senior author of the study, explained the objective of the research:

Our goal was to study the profile, or pharmacology, of these drugs. We wanted to decrease the potency and create a potential therapeutic. What we discovered exceeded our expectations.

Michael Michaelides, Ph.D.

Study Methodology and PET Imaging

To analyze the drug’s behavior, the researchers utilized a chemical formulation known as FNZ. This formulation was administered to rats and tagged with a radioisotope, allowing the team to employ positron emission tomography (PET) imaging.

The use of PET imaging enabled the researchers to track the drug in real time as it moved through the rat brain. This process helped the team verify the drug’s selectivity and its interaction with the mu-opioid receptors.

The resulting data showed that the modified compound maintained its potency as a pain reliever while avoiding the adverse effects typically associated with high-potency synthetic opioids.

Public Health Context and the Opioid Crisis

The search for safer analgesics is driven by the ongoing opioid crisis. Traditional opioids, including morphine, are essential for medical purposes but carry a high risk of misuse and dependence. Chronic exposure to these drugs can progressively rewire brain circuits that mediate reward and reinforcement, contributing to the development of opioid-use disorder.

Beyond addiction, traditional opioids often cause nausea, constipation, and the aforementioned respiratory depression.

Nora D. Volkow, M.D., director of the NIH’s National Institute on Drug Abuse (NIDA), emphasized the potential impact of this research on public health.

Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose. Developing a highly effective pain medication without these drawbacks would have enormous public health benefits.

Nora D. Volkow, M.D.

The discovery of a potent opioid with a positive safety profile was described as a surprise for a class of synthetic opioids that had been abandoned decades ago. While the study by Gomez et al. Provides a critical step toward the goal of safer pain relief, the research currently remains in the laboratory animal testing phase.